Kedrion Biopharma collects and fractionates plasma to produce therapies treating coagulation disorders, neurological conditions, immunodeficiencies, and Rh sensitisation. Operating 76 plasma centres and 7 production facilities across 5 countries, the company distributes 38 medicines to patients in over 100 nations, ranking as the fifth largest player in the plasma-derived sector worldwide. Kedrion thrives on rare connections: relationships between plasma donors, fractionation scientists, and patients whose lives depend on these medicines. This chain of hope extends to 5,200 employees working with medical communities and patient advocacy groups to deliver sustainable innovation for those with rare and ultra-rare diseases.
5200
Team Members
2001
Founded
Pharma
Sector
Hybrid
Work Environment
A world where rare disease patients access the therapies they need, where plasma donors create chains of hope, and where science and compassionate care unite to eliminate barriers for those with ultra-rare conditions.
Kedrion enhances lives through the development, production, and distribution of plasma-derived therapies that address unmet medical needs in rare and ultra-rare diseases.